• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases.
【24h】

Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases.

机译：自身免疫性胆汁淤积性肝病患者中存在高亲和力抗心磷脂抗体。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We studied the prevalence and clinical significance of anticardiolipin antibodies (aCL) in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) as similar data are missing. Ninety-nine PBC patients, 41 PSC, 228 HCV, 50 HBV, 111 with other non-viral and non-autoimmune liver disorders and 267 healthy were investigated. In order to evaluate the avidity of aCL, urea 2 M was used. IgG and/or IgM aCL were detected in 40% of PBC and PSC patients, in 26.2% of disease controls (P < 0.05) and 2.25% of healthy (P < 0.05). In PBC, IgG aCL associated with presence of cirrhosis, increased Mayo risk score and thrombocytopenia, while in PSC with longer disease duration and biochemical activity. Anti-beta2-GPI was detected in only three patients. Both in PBC and PSC, resistance of aCL to urea was high, similar to that observed in antiphospholipid syndrome (APS). We demonstrated a significantly higher prevalence of aCL in PBC and PSC compared to other liver diseases and healthy. aCL were associated with more severe disease in PBC and biochemical activity in PSC, but they rather seem to be "non-pathogenic" (co-factor-independent). However, their avidity was comparable with that of APS, indicating the need for prospective studies in order to address whether aCL in PBC and PSC may contribute to APS development or the progression of hepatic disease.
机译：我们研究了抗心磷脂抗体（aCL）在原发性胆汁性肝硬化（PBC）和原发性硬化性胆管炎（PSC）中的患病率和临床意义，因为缺少相似的数据。调查了99例PBC患者，41例PSC，228 HCV，50 HBV，111例其他非病毒和非自身免疫性肝病和267例健康患者。为了评估aCL的亲和力，使用了2 M尿素。在40％的PBC和PSC患者，26.2％的疾病对照（P <0.05）和2.25％的健康人群（P <0.05）中检测到IgG和/或IgM aCL。在PBC中，IgG aCL与肝硬化相关，增加了Mayo风险评分和血小板减少，而在PSC中，疾病持续时间和生化活性更长。仅三名患者检测到抗β2-GPI。在PBC和PSC中，aCL对尿素的抵抗力都很高，与在抗磷脂综合征（APS）中观察到的相似。我们证明与其他肝脏疾病和健康人群相比，PBC和PSC中aCL的患病率明显更高。 aCL与PBC中更严重的疾病和PSC中的生化活性有关，但它们似乎是“非致病性的”（不依赖辅因子）。然而，它们的亲和力与APS相当，表明需要进行前瞻性研究，以解决PBC和PSC中的aCL是否可能有助于APS的发展或肝病的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号